Literature DB >> 10683472

Immunogens of interest for the diagnosis of Campylobacter jejuni infections.

B Janvier1, S Ayraud, A Beby-Defaux, J Louis Fauchère.   

Abstract

In order to identify the C. jejuni immunogens of interest for the diagnosis of Campylobacter infections, we analyzed the humoral response of 153 patients by using complement fixation (CF) and western blot assays. A first group of 79 sera was from C. jejuni infected patients suffering from enteritis (n=16), Guillain-Barré syndrome (GBS) (n=40) and arthritis (n=23). A second group of 49 sera was from healthy blood donors and a third group consisted of 25 sera from children under 4 years old. Using the CF test, 88.6% of the C. jejuni infected patients were seropositive versus 28.5% of the healthy blood donors and none of the children. The Western blot assay allowed detection of antibodies directed against seven selected antigens ranging from 14 to 67 kDa. Three of these antigens with a molecular size of 29, 37 and 43 kDa were detected by 86.0%, 84.8% and 91.1% of the C. jejuni infected patients, respectively. These three antigens seem to be good candidates for the development of assays suitable for direct and indirect diagnosis of Campylobacter infections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683472     DOI: 10.1111/j.1574-695X.2000.tb01439.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  2 in total

1.  Recrudescent Campylobacter jejuni infection in an immunocompetent adult following experimental infection with a well-characterized organism.

Authors:  Shahida Baqar; David R Tribble; Marya Carmolli; Katrin Sadigh; Frederic Poly; Chad Porter; Catherine J Larsson; Kristen K Pierce; Patricia Guerry; Michael Darsley; Beth Kirkpatrick
Journal:  Clin Vaccine Immunol       Date:  2009-11-18

Review 2.  A review of serological tests to assist diagnosis of reactive arthritis: critical appraisal on methodologies.

Authors:  Tamara Tuuminen; Kari Lounamo; Marjatta Leirisalo-Repo
Journal:  Front Immunol       Date:  2013-12-04       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.